spinacine: structure given in first source; RN from Toxlit 4/88 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 162899 |
| CHEBI ID | 177618 |
| SCHEMBL ID | 3739922 |
| SCHEMBL ID | 10544160 |
| MeSH ID | M0155839 |
| Synonym |
|---|
| (6s)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| CHEBI:177618 |
| 59981-63-4 |
| l-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| spinacine |
| AKOS006279535 |
| 1h-imidazo(4,5-c)pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-, (s)- |
| eg040ze63k , |
| unii-eg040ze63k |
| (s)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| AKOS016370682 |
| SCHEMBL3739922 |
| (s)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| SCHEMBL10544160 |
| 4,5,6,7-tetrahydro-3h-imidazo(4,5-c)pyridine-6.alpha.-carboxylic acid |
| (s)-4,5,6,7-tetrahydro-1h-imidazo(4,5-d)pyridine-6-carboxylic acid |
| 3h-imidazo(4,5-c)pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-, (6s)- |
| (s)-4,5,6,7-tetrahydro-1h-imidazo(4,5-c)pyridine-6-carboxylic acid |
| j20.474i , |
| (6s)-4,5,6,7-tetrahydro-3h-imidazo(4,5-c)pyridine-6-carboxylic acid |
| spinacin |
| (-)-spinacine |
| l-spinacine |
| DTXSID80208688 |
| mfcd01318776 |
| (6s)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| CS-0063803 |
| AS-41213 |
| mfcd11518850 |
| Q27277160 |
| HY-W067716 |
| (s)-4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine-6-carboxylicacid |
| EN300-242063 |
| (6s)-1h,4h,5h,6h,7h-imidazo[4,5-c]pyridine-6-carboxylic acid |
| EX-A8005D |
| Excerpt | Reference | Relevance |
|---|---|---|
| " There were no adverse effects upon survival, growth or food intake." | ( Evaluation of the oral toxicity of spinacine hydrochloride in a 13-week study in rats. Allevi, P; Colombo, D; Corsini, E; Galli, CL; Marinelli, P; Orlando, L; Restani, P, 1989) | 0.55 |
| Class | Description |
|---|---|
| alpha-amino acid | An amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (57.65) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||